Efficacy of TriamHexal with and without Anti-VEGF(Bevacizumab) in treatment of keloidal leisons
Phase 3
Recruiting
- Conditions
- Keloidal lesions.Hypertrophic scarL91.0
- Registration Number
- IRCT20131119015455N5
- Lead Sponsor
- Esfahan University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 40
Inclusion Criteria
At least 1 keloidal lesion in the trunk and extremities
Age 18 to 70 years old
Informed consent to participate in the study
Exclusion Criteria
Pregnancy
Breastfeeding
History of cardiovascular diseases
Unwillingness to continue treatment
Not following up
Patients with severe side effects
Patients who have had previous keloid therapy
Infection at the injection site
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Improvement rate according to physician's point of view. Timepoint: 4, 8, 12 weeks and then 3 months after intervention. Method of measurement: Vancuver score and photography assessment by two blinded dermatologists.;Patient satisfaction score. Timepoint: 3 months and 6 months after intervention. Method of measurement: Visual Analogue Scale.
- Secondary Outcome Measures
Name Time Method Treatment side effects. Timepoint: 2 days after of each injection. Method of measurement: After the patient is instructed about possible side effects, the patient will be consulted by telephone to refer to the physician in case of severe side effects.